BRAIN+ ApS

Brain+ is addressing one of the largest health care challenges of our time, namely dementia. Currently, 1 in 3 seniors die with/of dementia in the US and globally 50 million people are diagnosed with dementia. Unfortunately, this figure is expected to more than triple to 152 million people by 2050. As we generally live longer and the prevention and treatment of the most common causes of death such as cancer and heart disease are getting more efficient, dementia is expected to become a leading cause of death by 2030 and is already the leading cause of death for women in the UK. Despite massive investments in research for treatments of dementia, there is still a high need for innovative and effective treatments for dementia. The good news is that Brain+ is leveraging new and innovative methods to create ground-breaking new treatments and provide these to patients in the shape of digital therapeutics. So far, initial trials indicate positive effects of these new methods for the treatment of cognitive decline in dementia. With a history of developing products and assets in this category since 2012 and 6 current and fully funded phase 2 studies underway with prominent development partners, such as Oxford University, Brain+ is uniquely positioned to emerge as a global market leader within Digital Therapeutics (DTx) for Alzheimer's and dementia and is expected to benefit from a DTx market that is growing significantly.